Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Oktober 2025 15:39 ET | Quelle: MetasTx LLC

NJ-Founded MetasTx Fast-Tracks Precision Approach to Stop Prostate Cancer Spread; NCI-Backed Diagnostic in Proof-of-Concept, Next-Gen KIT Inhibitor Advancing Toward First-in-Human

NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.
25. Juni 2025 07:08 ET | Quelle: MetasTx LLC

MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer

MetasTx has been awarded a NCI SBIR grant for its integrated diagnostic and therapeutic platform aimed at predicting and preventing prostate cancer.
17. Oktober 2017 07:58 ET | Quelle: The Jackson Labratory

The Jackson Laboratory and Seven Bridges Collaborate to Build Centralized Data Platform to Advance Cancer Research

FARMINGTON, Conn., and BOSTON, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- The Jackson Laboratory (JAX), a nonprofit biomedical research institution, and Seven Bridges, the leading biomedical data...